BIO 2015 Dispatches: Can Expanding FDA's 'Breakthrough' Program Be An Answer To High Drug Costs?
This article was originally published in The Pink Sheet Daily
Executive Summary
America's Health Insurance Plans interim CEO Dan Durham says taking an indication-based approach, rather than the current product-specific approach, to awarding the designation would allow later-in-class products to reach market more quickly and help drive down the high cost of novel treatments approved under the expedited pathway.